What is Kimia Biosciences Ltd (530313) share price return in the past 10 years?

Kimia Biosciences Ltd share price has appreciated 20.8% annually (CAGR) over the past ten years.

What is the share price of Kimia Biosciences Ltd (530313)?

Company share prices are keep on changing according to the market conditions. The current trading price of Kimia Biosciences Ltd (530313) on 04-Jun-2026 16:59:59 at 16:59 is 33.11.

What is the P/E ratio of Kimia Biosciences?

The latest standalone P/E ratio of Kimia Biosciences as of 04-Jun-2026 is 21.07.

What is the P/B ratio of Kimia Biosciences Ltd (530313)?

The latest standalone P/B ratio of Kimia Biosciences Ltd (530313) as of 04-Jun-2026 is 8.84.

What is the 52-week high and low of Kimia Biosciences Ltd (530313)?

The 52-week high of Kimia Biosciences Ltd (530313) is Rs. 86.85 and the 52-week low is Rs. 23.20.

Kimia Biosciences Ltd (530313) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Kimia Biosciences Ltd (530313)
Brand: Kimia Biosciences

Kimia Biosciences Ltd (530313)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530313 NSE: Pharmaceuticals & Drugs | Small Cap | Kimia Biosciences Share Price

Kimia Biosciences Ltd (530313)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530313 NSE: Pharmaceuticals & Drugs | Small Cap | Kimia Biosciences Share Price

Key Metrics

Valuation Multiples

Market Cap

₹157 Cr.

Current Price

₹33.1

52-Week Low / High

₹23 / 87

TTM EPS

₹1.6

TTM Sales

₹115 Cr.

Book Value per Share

₹3.8

P/E Ratio

21.07

Industry PE

46.5

Price to Book (P/B)

8.84

Lower than its 5-year historical median

Price to Sales (P/S)

1.36

Lower than its 5-year historical median

EV/EBITDA

11.99

Lower than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

186.70%

Outperforms industry median

Return on Capital Employed (ROCE)

42.18%

Outperforms industry median

Return on Assets (ROA)

9.44%

Operating Profit Margin

17%

Net Profit Margin

8.08%

Gross Profit Margin

14.3%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

13.39%

Operating Profit Growth (1 Year)

Net Profit Growth (1 Year)

Asset Quality

Promoter Holding

74.94%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹13 Cr.

Equity

₹4.7 Cr.

Face Value

₹1

All Time Low / High

₹0.60 / 86.85

Kimia Biosciences stock performance

Key Ratios

Check Before You Invest

Quality

Locked

Valuation

Locked

Price Trend

Locked

Q.1 Is Kimia Biosciences Ltd a good quality company?

Kimia Biosciences Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Kimia Biosciences Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Kimia Biosciences Ltd vs industry peers?

Kimia Biosciences Ltd revenue CAGR is 2.27%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.

Q.1 Promoter shareholding and pledge status of Kimia Biosciences Ltd?

Promoters hold 74.94% of the Kimia Biosciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Kimia Biosciences Ltd over the last decade?

Over the last 5 year(s), the stock has delivered a CAGR of -3.18% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	-216.8%	-18.3%	11.8%	16.9%	8.9%	16.1%	-2.3%	-14.3%	-4.2%	42.2%	-
Value Creation Index ⓘ	NA	NA	-0.2	0.2	-0.4	0.2	-1.2	-2.0	-1.3	2.0	-
Growth Parameters ⓘ
Sales ⓘ	0.2	1.5	76.3	93.9	106	133	125	129	105	119	115
Sales YoY Gr.	-	668.4%	5,126.7%	23.1%	13.2%	24.9%	-5.9%	2.9%	-18.4%	13.4%	-
Adj EPS ⓘ	-5.5	-1.7	0.9	2.7	0.4	0.9	-0.8	-1.6	-1.1	1.9	1.6
YoY Gr.	-	NA	NA	189.4%	-85.7%	125.6%	-194.3%	NA	NA	NA	-
BVPS (₹) ⓘ	-5.3	-6.3	-0.2	2.4	2.9	3.9	3.2	1.2	0.1	2.1	3.8
Adj Net Profit ⓘ	-4.1	-1.2	1.4	4	1.8	4.2	-3.9	-7.6	-5.3	9.2	7
Cash Flow from Ops. ⓘ	-6	-0.7	-7.1	-2.7	0.3	6	8	-6.8	14.5	21.3	-
Debt/CF from Ops. ⓘ	-1.1	-13.2	-4.2	-11.6	110	7.5	5.1	-7.8	3	1.5	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	104.5%	2.3%	-1.6%	13.4%
Adj EPS ⓘ	NA	37.8%	NA	NA
BVPSⓘ	NA	-5.9%	-12.5%	2914.3%
Share Price	20.8%	-5.3%	-1.1%	-30.7%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	220.1	29	-117.5	94.7	18.5	26.2	-23.6	-74.7	-181.4	178.7	53.6
Op. Profit Mgn % ⓘ	-1759.4	-56.5	3.2	6.1	4.8	6.3	0.5	-2.8	-0.4	17	12.4
Net Profit Mgn % ⓘ	-2122.9	-84.5	1.8	4.2	1.7	3.1	-3.1	-5.9	-5	7.7	6.5
Debt to Equity ⓘ	-1.7	-2.1	91.2	7.4	2.5	2.4	2.7	9.7	131.1	3.3	1.3
Working Cap Days ⓘ	1,996	354	102	170	184	179	207	221	250	210	96
Cash Conv. Cycle ⓘ	424	55	45	84	93	88	88	90	73	37	-2

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	0	1	76	94	106	133	125	129	105	119
Operating Expenses ⓘ +	4	2	74	88	102	124	124	134	105	99
Manufacturing Costs	0	0	3	4	6	9	10	11	8	8
Material Costs	0	0	59	71	80	97	92	96	75	71
Employee Cost	2	1	8	9	11	14	15	16	15	14
Other Costs ⓘ	1	1	4	5	5	5	7	10	7	6
Operating Profit ⓘ	-3	-1	2	6	4	8	1	-5	-0	20
Operating Profit Margin (%)	-1,759.4%	-67.2%	3.2%	5.9%	4.2%	6.3%	0.5%	-4.0%	-0.5%	17.0%
Other Income ⓘ +	0	1	1	1	1	2	1	1	2	1
Exceptional Items ⓘ	0	0	0	0	0	0	0	-1	0	0
Interest ⓘ	1	0	1	2	3	3	4	4	5	5
Depreciation ⓘ	0	0	1	1	2	2	3	3	3	3
Profit Before Tax ⓘ	-4	-1	2	4	1	6	-5	-12	-7	14
Tax ⓘ	0	-0	-0	-0	-0	0	-1	-3	-2	4
Profit After Tax	-4	-1	2	4	1	5	-4	-9	-5	10
PAT Margin (%)	-2,109.8%	-63.7%	2.2%	4.1%	1.3%	3.9%	-3.0%	-7.3%	-5.1%	8.1%
Adjusted EPS (₹)	-5.5	-1.3	1.1	2.6	0.3	1.1	-0.8	-2.0	-1.1	2.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Kimia Biosciences - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	-4	-5	0	4	13	18	15	5	0	10
Share Capital ⓘ	7	7	2	2	5	5	5	5	5	5
Reserves ⓘ	-11	-12	-2	2	9	14	10	1	-4	5
Debt +	7	9	29	30	31	41	39	51	41	30
Long Term Debt	7	9	25	24	24	28	24	31	21	10
Short Term Debt	0	0	5	5	6	13	15	20	20	20
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	0	0	19	18	27	31	40	47	40	50
Others Liabilities ⓘ	1	7	9	14	15	16	14	15	13	19
Total Liabilities ⓘ	4	12	58	65	86	107	109	117	94	109
Fixed Assets
Net Fixed Assets ⓘ +	3	7	13	16	18	28	35	34	32	33
Gross Block	12	7	15	19	22	34	44	46	47	52
Accumulated Depreciation	8	0	2	3	4	6	9	12	16	19
CWIP ⓘ	0	3	2	2	6	6	0	1	1	0
Investments ⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	0	1	10	16	20	24	37	48	31	35
Trade Receivables	0	0	29	29	37	42	30	31	28	37
Cash Equivalents	0	0	2	1	1	2	1	0	1	1
Others Assets ⓘ	1	1	2	1	3	5	6	4	3	4
Total Assets ⓘ	4	12	58	65	86	107	109	117	94	109

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-6	-1	-7	-3	0	6	8	-7	15	21
PBT ⓘ	-4	-1	2	4	1	6	-5	-12	-7	14
Adjustment ⓘ	1	1	1	1	4	4	6	8	8	7
Changes in Working Capital ⓘ	-3	-0	-10	-8	-5	-3	7	-2	14	1
Tax Paid ⓘ	0	-0	0	-0	0	0	-0	0	0	0
Cash Flow From Investing Activity ⓘ +	-0	-6	-2	-2	-9	-14	-1	-3	-1	-5
Capex	-0	-6	-3	-3	-9	-14	-2	-3	-2	-5
Net Investments	0	0	0	0	0	-0	1	-0	-0	-0
Others ⓘ	0	0	0	0	0	0	0	0	0	-0
Cash Flow From Financing Activity ⓘ +	6	7	10	4	8	8	-8	10	-13	-17
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	7	3	11	4	3	4	-3	7	-9	-11
Interest Paid ⓘ	-1	-0	-1	-1	-1	-2	-3	-3	-4	-6
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	4	-0	1	7	7	-2	5	-0	0
Net Cash Flow ⓘ	0	0	0	-0	0	0	-0	-0	-0	0

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	N/A	N/A	N/A	243.83	16.47	32.19	-22.22	-91.91	N/A	186.7
ROCE (%)	N/A	N/A	N/A	16.94	8.94	16.13	-2.32	-14.3	N/A	42.18
Asset Turnover Ratio	0.04	0.18	2.18	1.52	1.41	1.38	1.16	1.14	0.99	1.17
PAT to CFO Conversion(x)	N/A	N/A	-3.5	-0.75	0	1.2	N/A	N/A	N/A	2.1
Working Capital Days
Receivable Days	345.50	20.80	70.60	113.90	114.10	108.80	105.20	86.30	101.20	98.70
Inventory Days	143.50	83.50	24.30	49.90	62.50	60.50	88.70	121.10	137.50	100.30
Payable Days	2,391.50	260	61.50	95.40	100.60	108.10	140.40	164.90	210	233

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Kimia Biosciences Ltd FAQs

The current trading price of Kimia Biosciences on 04-Jun-2026 16:59 is ₹33.11.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Kimia Biosciences stood at ₹156.7 Cr

The latest P/E ratio of Kimia Biosciences as of 03-Jun-2026 is 21.07.

The latest P/B ratio of Kimia Biosciences as of 03-Jun-2026 is 8.84.

The 52-week high of Kimia Biosciences is ₹86.85 and the 52-week low is ₹23.20.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kimia Biosciences is ₹115 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Kimia Biosciences Ltd is a below average quality company.

The key valuation ratios of Kimia Biosciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Kimia Biosciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Kimia Biosciences Ltd

No data to display

Kimia Biosciences Ltd (530313)

Kimia Biosciences Ltd (530313)

Kimia Biosciences stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Kimia Biosciences - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Kimia Biosciences Ltd FAQs

About Kimia Biosciences Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Kimia Biosciences Ltd (530313)

Kimia Biosciences Ltd (530313)

Kimia Biosciences stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Kimia Biosciences - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Kimia Biosciences Ltd FAQs

What is the share price of Kimia Biosciences?

What is the market cap of Kimia Biosciences?

What is the P/E ratio of Kimia Biosciences?

What is the P/B ratio of Kimia Biosciences?

What is the 52-week high and low of Kimia Biosciences?

What is the TTM revenue of Kimia Biosciences?

Is Kimia Biosciences Ltd a good quality company?

Is Kimia Biosciences Ltd undervalued or overvalued?

Is Kimia Biosciences Ltd a good buy now?

About Kimia Biosciences Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.